Innate Pharma S.A.
Stock Forecast, Prediction & Price Target
Innate Pharma S.A. Financial Estimates
Innate Pharma S.A. Revenue Estimates
Innate Pharma S.A. EBITDA Estimates
Innate Pharma S.A. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $12.11M N/A | $49.63M 309.83% | $51.90M 4.55% | Avg: $96.85M Low: $66.78M High: $126.92M avg. 86.61% | Avg: $123.51M Low: $70.32M High: $176.70M avg. 27.52% | Avg: $68.07M Low: $38.75M High: $97.39M avg. -44.88% | Avg: $138.18M Low: $78.67M High: $197.70M avg. 102.99% |
Net Income
% change YoY
| $-59.13M N/A | $-99.10M -67.58% | $-7.57M 92.36% | Avg: $20.85M Low: $14.15M High: $27.55M avg. 375.46% | Avg: $22.80M Low: $10.03M High: $35.57M avg. 9.37% | Avg: $-19.89M Low: $-31.03M High: $-8.75M avg. -187.23% | Avg: $28.64M Low: $12.60M High: $44.68M avg. 244.00% |
EBITDA
% change YoY
| $-36.88M N/A | $33.75M 191.51% | $-1.83M -105.44% | Avg: $-464.62K Low: $-608.87K High: $-320.37K avg. 74.73% | Avg: $-592.50K Low: $-847.67K High: $-337.33K avg. -27.52% | Avg: $-326.55K Low: $-467.19K High: $-185.92K avg. 44.88% | Avg: $-662.88K Low: $-948.36K High: $-377.40K avg. -102.99% |
EPS
% change YoY
| -$0.74 N/A | -$1.24 -67.56% | -$0.09 92.41% | Avg: $0.26 Low: $0.18 High: $0.34 avg. 375.44% | Avg: $0.28 Low: $0.12 High: $0.44 avg. 9.37% | Avg: -$0.25 Low: -$0.39 High: -$0.11 avg. -187.23% | Avg: $0.36 Low: $0.16 High: $0.56 avg. 244.00% |
Operating Expenses
% change YoY
| $59.93M N/A | $66.06M 10.22% | $64.57M -2.26% | Avg: $80.23M Low: $55.32M High: $105.14M avg. 24.26% | Avg: $102.32M Low: $58.25M High: $146.38M avg. 27.52% | Avg: $56.39M Low: $32.10M High: $80.68M avg. -44.88% | Avg: $114.47M Low: $65.17M High: $163.77M avg. 102.99% |
FAQ
What is Innate Pharma S.A. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 110.40% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is 14.15M, average is 20.85M and high is 27.55M.
What is Innate Pharma S.A. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 43.06% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $66.78M, average is $96.85M and high is $126.92M.
What is Innate Pharma S.A. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 110.39% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is $0.18, average is $0.26 and high is $0.34.